Literature DB >> 22949088

Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.

Warren E Regelmann1, Michael S Schechter, Jeffrey S Wagener, Wayne J Morgan, David J Pasta, Eric P Elkin, Michael W Konstan.   

Abstract

BACKGROUND: A standard definition of pulmonary exacerbation based on signs and symptoms would be useful for categorizing cystic fibrosis (CF) patients and as an outcome measure of therapy. The frequently used definition of treatment with intravenous antibiotics varies with practice patterns. One approach to this problem is to use large data sets which include a patient's signs and symptoms along with their clinician's decision to treat with antibiotics for the diagnosis of pulmonary exacerbation. Previous analysis of such a data set, the Epidemiologic Study of Cystic Fibrosis (ESCF), found that new crackles, increased cough, increased sputum, and weight decline were the four clinical characteristics most strongly influencing providers to treat young CF patients for a pulmonary exacerbation. The objectives of this study were to confirm that these four characteristics influence the decision to treat with antibiotics for a pulmonary exacerbation in young CF patients; to evaluate their implications for future nutritional status and lung function; and to assess the effect of antibiotic treatment on these characteristic signs and symptoms.
METHODS: This was an observational, longitudinal cohort study of clinical care in children <6 years old cared for at sites participating in ESCF.
RESULTS: Using data from children not included in the previous ESCF study, we confirmed that these four characteristics were significantly associated with the likelihood of physicians prescribing antibiotics to treat a pulmonary exacerbation. The number of these characteristics present at a single clinic visit before age 6 predicted hospitalization rate over the next year, the weight-for-age z-score, and the forced expiratory volume in 1 sec (FEV1) percent predicted at age 7. Treatment with antibiotics was associated with a greater decrease in the proportion of children with crackles, cough, and Pseudomonas aeruginosa at a follow-up visit within 6 months.
CONCLUSIONS: New crackles, increased cough, increased sputum, and decline in weight percentile at a single clinic visit increase the risk of future malnutrition, hospitalization, and airflow obstruction in young children with CF. Treatment with antibiotics mitigates some of these signs and symptoms by the first follow-up visit. The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949088      PMCID: PMC4102401          DOI: 10.1002/ppul.22658

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

1.  Defining a pulmonary exacerbation in cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; J Williams-Warren; M Pepe; A Smith; A B Montgomery; B Ramsey
Journal:  J Pediatr       Date:  2001-09       Impact factor: 4.406

2.  Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!

Authors:  Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2004-04-01       Impact factor: 21.405

Review 3.  An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all.

Authors:  Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

4.  Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Authors:  W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker
Journal:  Pediatr Pulmonol       Date:  1999-10

Review 5.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

6.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

7.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

8.  Pulmonary exacerbations in cystic fibrosis.

Authors:  Harvey R Rabin; Steven M Butler; Mary Ellen B Wohl; David E Geller; Andrew A Colin; Daniel V Schidlow; Charles A Johnson; Michael W Konstan; Warren E Regelmann
Journal:  Pediatr Pulmonol       Date:  2004-05

9.  Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Authors:  Charles Johnson; Steven M Butler; Michael W Konstan; Wayne Morgan; Mary Ellen B Wohl
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation.

Authors:  Kenneth J Rothman; Charles E Wentworth
Journal:  Epidemiology       Date:  2003-01       Impact factor: 4.822

View more
  14 in total

1.  Pulmonary radiographic findings in young children with cystic fibrosis.

Authors:  Jesiana Ferreira Pedrosa; Cássio da Cunha Ibiapina; Cristina Gonçalves Alvim; Paulo Augusto Moreira Camargos; Fabiana Paiva Martins; Elizabet Vilar Guimarães; Renata Marcos Bedran
Journal:  Pediatr Radiol       Date:  2014-07-22

Review 2.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Authors:  Zarmina Ehsan; John P Clancy
Journal:  Future Microbiol       Date:  2015-11-17       Impact factor: 3.165

Review 3.  Wheezing in Infancy: An Overview of Recent Literature.

Authors:  Christine Muglia; John Oppenheimer
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-11       Impact factor: 4.806

4.  Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Authors:  Don B Sanders; Qianqian Zhao; Zhanhai Li; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2017-09-07

5.  The expression of Mirc1/Mir17-92 cluster in sputum samples correlates with pulmonary exacerbations in cystic fibrosis patients.

Authors:  Kathrin Krause; Benjamin T Kopp; Mia F Tazi; Kyle Caution; Kaitlin Hamilton; Asmaa Badr; Chandra Shrestha; Dmitry Tumin; Don Hayes; Frank Robledo-Avila; Luanne Hall-Stoodley; Brett G Klamer; Xiaoli Zhang; Santiago Partida-Sanchez; Narasimham L Parinandi; Stephen E Kirkby; Duaa Dakhlallah; Karen S McCoy; Estelle Cormet-Boyaka; Amal O Amer
Journal:  J Cyst Fibros       Date:  2017-12-11       Impact factor: 5.482

6.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

Review 7.  Epidemiologic Study of Cystic Fibrosis: 25 years of observational research.

Authors:  Michael W Konstan; David J Pasta; Donald R VanDevanter; Jeffrey S Wagener; Wayne J Morgan
Journal:  Pediatr Pulmonol       Date:  2021-01-12

8.  Variability of FEV1 and criterion for acute pulmonary exacerbation.

Authors:  Bradlee A Jenkins; Loyd Lee Glenn
Journal:  Front Pediatr       Date:  2014-10-17       Impact factor: 3.418

9.  Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.

Authors:  Nicole Mayer-Hamblett; George Retsch-Bogart; Margaret Kloster; Frank Accurso; Margaret Rosenfeld; Gary Albers; Philip Black; Perry Brown; AnneMarie Cairns; Stephanie D Davis; Gavin R Graff; Gwendolyn S Kerby; David Orenstein; Rachael Buckingham; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2018-11-01       Impact factor: 30.528

Review 10.  Treatment of pulmonary exacerbations in cystic fibrosis.

Authors:  Christabella Ng; Tejaswi Nadig; Alan R Smyth; Patrick Flume
Journal:  Curr Opin Pulm Med       Date:  2020-11       Impact factor: 2.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.